ADCs, also known as antibody drug conjugates, are highly tailored biopharmaceutical therapies that combine monoclonal antibodies designed to target certain tumor cells' surface antigens with highly potent anticancer chemicals and are joined by chemical linkers.
In recent years, the Antibody Drug Conjugates (ADC) market has emerged as a groundbreaking force in the field of oncology, showcasing its potential to revolutionize cancer treatment strategies. ADCs represent a convergence of ... Read more
